You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股异动 | 开拓药业-B(9939.HK)涨超5% 新药研究申请获国家药监局CDE批准
格隆汇 04-16 10:25
格隆汇4月16日丨开拓药业-B(9939.HK)现报37.45港元,涨5.05%,暂成交3822万港元,最新总市值138亿港元。开拓药业昨日晚间公布,于4月14日,GT20029用于雄激素性脱发及痤疮适应症的新药研究("IND")申请("临床试验")已获中国国家药品监督管理局药品审评中心("CDE")批准。临床试验为随机、双盲、安慰剂对照的I期研究,旨在评估GT20029酊凝胶在健康受试者中单、多次给药的安全性及药代动力学特性。集团正准备临床试验,并预期将于2021年第三季开始招募受试者。据董事所知,GT20029是全球首个进入临床阶段的外用PROTAC化合物。集团亦正在准备GT20029于美国的IND申请。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account